News
- Author:
- Neil Osterweil
Publish date: December 14, 2022
New research supports establishing a national exchange of alloantibody data, to save lives and cut costs in transfusion medicine.
News
- Author:
- Neil Osterweil
Publish date: December 14, 2022
The POLAR 16-gene mRNA signature accurately identified patients who were unlikely to benefit from radiotherapy after breast-conserving surgery.
News
- Author:
- Neil Osterweil
Publish date: December 13, 2022
The novel antibody talquetamab may buy time for patients with multiple myeloma (MM) for whom few other options remain.
News
- Author:
- Neil Osterweil
Publish date: December 13, 2022
Researchers calculated that a costly new treatment being developed for sickle cell disease (SCD) promises to be worth the price.
News
- Author:
- Neil Osterweil
Publish date: December 12, 2022
“We don’t get to use the ‘eliminate’ word all that often with a disease that’s taking thousands or tens of thousands – or worldwide, hundreds of th...
News
- Author:
- Neil Osterweil
Publish date: December 12, 2022
Nearly 70% of patients with hormone receptor-positive breast cancers with low levels of HER2 had pathological response to the antibody-drug conjuga...
News
- Author:
- Neil Osterweil
Publish date: December 11, 2022
Research on pediatric blood cancers found that high-dose methotrexate does not help cut the risk for central nervous system relapse.
News
- Author:
- Neil Osterweil
Publish date: December 11, 2022
New research on treating acute myeloid leukemia suggested that some patients may safely go straight to stem cell transplantation.
News
- Author:
- Neil Osterweil
Publish date: December 9, 2022
The investigational selective estrogen receptor degrader showed efficacy in advanced ER+/HER2– breast cancers, including patients with ESR1 mutatio...
News
- Author:
- Neil Osterweil
Publish date: December 9, 2022
Ribociclib plus endocrine therapy resulted in high response rates and double progression-free survival over combo chemotherapy.
News
- Author:
- Neil Osterweil
Publish date: December 9, 2022
Tumor microenvironment of metastasis doorways predicted worse outcomes in Black women with residual ER+/HER2– cancer after neoadjuvant chemotherapy...
News
- Author:
- Neil Osterweil
Publish date: December 7, 2022
Fresh research to be unveiled at the 2022 American Society of Hematology conference seems to overturn conventional wisdom across a range of issues....
News
- Author:
- Neil Osterweil
Publish date: November 21, 2022
The findings show that “progression to LSM-defined cirrhosis by VCTE is strongly associated with poor clinical outcomes.”
News
- Author:
- Neil Osterweil
Publish date: November 18, 2022
Vaccinate patients with rheumatic and musculoskeletal disease against flu and other vaccine-preventable disease whenever possible, experts say.
News
- Author:
- Neil Osterweil
Publish date: November 18, 2022
Given the small size of the open-label study, with only 25 patients in each arm, the results should be considered as proof of concept and need to b...
